Phase I Study of ELI-002 in Patients with KRAS Mutated Solid Tumors, including Pancreatic Cancer
The purpose of this phase I study is to evaluate the safety and feasibility of ELI-002 immunotherapy in patients with KRAS mutated solid tumors, including pancreatic cancer.
Study ID: ELI-002-001
Trial Phase: Phase I
Trial Sponsor: Elicio Therapeutics
Therapies Used in This Trial: ELI-002 2P